EUVIMEDEUVIMED entdecken
Crossref

Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway

Jun-Kyu Byun, Gwon-Soo Jung

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2024.150425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Jun-Kyu Byun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu, 41566, South Korea. Hauptthemen laut MEDLINE: Smad3 Protein, Fibrosis, Fibroblast Growth Factors, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Kyungpook National University, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factor 21 (FGF21), a well-known regulator of metabolic disorders, exhibits the potential to prevent renal fibrosis by negatively regulating the transforming growth factor β (TGF-β)/Smad3 signaling pathway. Gemigliptin and other dipeptidyl peptidase-4 inhibitors are frequently used for the management of patients with type 2 diabetes. However, the protective effect of gemigliptin against renal fibrosis, particularly its potential to upregulate the expression of FGF21, remains incompletely understood. This study assessed the renoprotective effects of gemigliptin against TGF-β-induced renal fibrosis by enhancing the expression of FGF21 in the cultured human proximal tubular epithelial cell line HK-2. Treatment with FGF21 effectively prevented TGF-β-induced renal fibrosis by attenuating the TGF-β/Smad3 signaling pathway. Similarly, gemigliptin exhibited protective effects against TGF-β-induced renal fibrosis by mitigating TGF-β/Smad3 signaling through the upregulation of FGF21 expression. However, the protective effects of gemigliptin were blocked when FGF21 expression was knocked down in TGF-β-treated HK-2 cells. These results indicate that gemegliptin has the potential to exhibit protective effects against TGF-β-induced renal fibrosis by elevating FGF21 expression levels in cultured human proximal tubular epithelial cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad3 ProteinFibrosisFibroblast Growth FactorsSignal TransductionTransforming Growth Factor betaPyrimidinesPiperidonesHumansCell LineKidney DiseasesKidney

Stichwörter der Autor:innen

FGF21GemigliptinHK-2Renal fibrosisSmad3TGF-β

Substanzen

Smad3 ProteinFibroblast Growth FactorsLC15-0444Transforming Growth Factor betaSMAD3 protein, humanPyrimidinesPiperidonesfibroblast growth factor 21FGF21 protein, human

Autor:innen und Institutionen

  • Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu, 41566, South Korea.
  • New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, 41061, South Korea. Electronic address: gsjung@kmedihub.re.kr.

Förderung

  • Kyungpook National University
  • National Research Foundation of Korea

Zitieren

APA

Byun, J. K., & Jung, G. S. (2024). Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150425

Vancouver

Byun JK, Jung GS. Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150425

BibTeX
@article{Byun2024,
  author = {Byun, Jun-Kyu and Jung, Gwon-Soo},
  title = {Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2024.150425}
}
Kostenlos starten →